The drug candidate, trevogrumab, in combination with Novo Nordisk's popular obesity drug Wegovy, chemically known as semaglutide, helped patients preserve muscle and increase fat loss in patients, ...

Novo Nordisk was Europe's most valuable company, with a big lead on obesity drugs with its runaway hits Ozempic and Wegovy.

The global weight-loss drug market is experiencing exceptional growth, projected to expand from around $144.6 billion in 2023 ...

Another is to find stocks with relatively affordable price tags per share. Although it's sometimes the case that the most ...

Novo Nordisk (NVO) makes Ozempic, the best-known GLP-1 drug out today. And until quite recently, the Danish pharma giant ...

Novo Nordisk continues to deliver strong revenue, profit growth, and high economic profitability. Read why I rate NVO stock a ...

Regional equity markets closed in positive territory on Tuesday, building positive momentum after a muted trading session on ...

Novo Nordisk’s new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and navigate other challenges ...

Despite this success, recent market challenges and a decline in ... Despite the leadership change at Novo Nordisk causing the stock price to stumble, a 10.4% increase in the company’s stock ...

The BMO Capital analyst concluded that without meaningful strategic changes, Novo Nordisk might continue to struggle. The firm’s reiteration of the "Market Perform" rating and the $64.00 price target ...

HONG KONG (AP) — Asian shares fell Monday and U.S. futures and the dollar weakened after Moody’sRatings downgraded the sovereign credit rating for the United States because of its failure to stem a ...